A systematic review of randomised controlled trials on topical nasal steroids
Copyright © 2024 Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale, Rome, Italy..
Introduction: Intranasal corticosteroids (INCs) are the first line of therapy for chronic sinonasal conditions such as rhinitis and rhinosinusitis. Among these, one of the most frequently used is beclomethasone dipropionate (BDP). Over the years many studies have evaluated the efficacy of BDP as part of therapy for chronic rhinosinusitis (CRS) and allergic rhinitis (AR) along with nasal washes, which seems to be very well tolerated.
Objective: To analyse the data in the literature regarding the various therapeutic regimens of BDP in different sinonasal disease and their efficacy and tolerability.
Materials and methods: Using different search engines, the posology, efficacy, and tolerability of BDP were reviewed and a total of 64 full-length articles were examined for eligibility. After applying inclusion and exclusion criteria, 4 articles were reviewed.
Results: BDP is among the group of INCs with significant improvement of nasal symptoms and has good efficacy and safety.
Conclusions: BDP nasal spray is one of the most frequently prescribed INC for rhinitis and rhinosinusitis. Treatment with BDP resulted in significant and clinically meaningful improvements in nasal symptoms associated with AR and CRS. BDP is well tolerated, and the safety profile is similar to that of placebo in most patients. These results, in conjunction with the significant benefit reported in subjects with CRS and AR, provide convincing evidence of the overall effectiveness of BDP for the treatment of the full spectrum of sinonasal disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale - 44(2024), 2 vom: 07. Apr., Seite 71-75 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zeroli, Chiara [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.04.2024 Date Revised 29.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.14639/0392-100X-N2745 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371404762 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371404762 | ||
| 003 | DE-627 | ||
| 005 | 20240501233314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240424s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14639/0392-100X-N2745 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1394.xml |
| 035 | |a (DE-627)NLM371404762 | ||
| 035 | |a (NLM)38651550 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zeroli, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A systematic review of randomised controlled trials on topical nasal steroids |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2024 | ||
| 500 | |a Date Revised 29.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale, Rome, Italy. | ||
| 520 | |a Introduction: Intranasal corticosteroids (INCs) are the first line of therapy for chronic sinonasal conditions such as rhinitis and rhinosinusitis. Among these, one of the most frequently used is beclomethasone dipropionate (BDP). Over the years many studies have evaluated the efficacy of BDP as part of therapy for chronic rhinosinusitis (CRS) and allergic rhinitis (AR) along with nasal washes, which seems to be very well tolerated | ||
| 520 | |a Objective: To analyse the data in the literature regarding the various therapeutic regimens of BDP in different sinonasal disease and their efficacy and tolerability | ||
| 520 | |a Materials and methods: Using different search engines, the posology, efficacy, and tolerability of BDP were reviewed and a total of 64 full-length articles were examined for eligibility. After applying inclusion and exclusion criteria, 4 articles were reviewed | ||
| 520 | |a Results: BDP is among the group of INCs with significant improvement of nasal symptoms and has good efficacy and safety | ||
| 520 | |a Conclusions: BDP nasal spray is one of the most frequently prescribed INC for rhinitis and rhinosinusitis. Treatment with BDP resulted in significant and clinically meaningful improvements in nasal symptoms associated with AR and CRS. BDP is well tolerated, and the safety profile is similar to that of placebo in most patients. These results, in conjunction with the significant benefit reported in subjects with CRS and AR, provide convincing evidence of the overall effectiveness of BDP for the treatment of the full spectrum of sinonasal disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a allergic rhinitis | |
| 650 | 4 | |a beclomethasone dipropionate | |
| 650 | 4 | |a chronic rhinosinusitis | |
| 650 | 4 | |a rhinitis | |
| 650 | 4 | |a topical nasal steroids | |
| 650 | 7 | |a Beclomethasone |2 NLM | |
| 650 | 7 | |a KGZ1SLC28Z |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a Gorica, Armela |e verfasserin |4 aut | |
| 700 | 1 | |a Monti, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Castelnuovo, Paolo Giocondo Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Bignami, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Macchi, Alberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale |d 1985 |g 44(2024), 2 vom: 07. Apr., Seite 71-75 |w (DE-627)NLM01279046X |x 1827-675X |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:2 |g day:07 |g month:04 |g pages:71-75 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14639/0392-100X-N2745 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 2 |b 07 |c 04 |h 71-75 | ||